Testing EG110A injections for bladder leakage after spinal cord injury
Tests EG110A bladder injections in adults with spinal cord injury and incontinence.
Key facts
- Who runs it
- Cyllene Therapeutics
- Where
- Ann Arbor, Columbus, Downey, Houston, and Philadelphia, United StatesSee the 5 sites
- Trial code
- Registry title
- Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 16 people, planned
- Started
- 8 Jan 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- EG110A
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bladder leakage caused by an overactive bladder after a spinal cord injury. They must use a catheter regularly to empty the bladder, and their leakage must continue despite standard treatment.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Stable spinal cord injury above the sacral level, caused by trauma, ASIA grade A, B, C, D or E. The injury happened at least 12 months before screening and no more than 12 years ago. Leakage from overactive bladder confirmed by bladder pressure tests for at least 3 months. At least 8 leakage episodes in a week.
- Earlier treatment
- One of two paths. 1: Treated with pills for at least 3 months, with side effects too hard to bear or not enough benefit. You do not want BoNT/A, and surgery would be the next step. 2: Not enough benefit from BoNT/A, last given at least 6 months before screening and first started no more than 7 years ago. Surgery would be the next step.
Main reasons for not taking part
- Past or current tumor or cancer affecting the spine or spinal cord, or another unstable cause of the injury.
- Active mouth or genital herpes sores. You can be screened again at least 4 weeks after the sore has healed.
- Cancer treatment or radiotherapy 4 weeks or less before screening, with side effects that have not gone away or settled.
The registry criteria, word for word
Show all 7 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Participant has stable supra-sacral traumatic SCI with American Spinal Injury Association (ASIA) Impairment Scale grade A, B, C, D or E which occurred at least 12 months before Screening but no more than 12 years post injury
- Participant has UI due to urodynamically-confirmed NDO for at least 3 months prior to Screening
- Participant has:; been treated for NDO for at least 3 months prior to Screening with an adequate course of oral pharmacotherapy(ies) and/or has had intolerable side-effects and/or exhibited an inadequate response in the opinion of the investigator and participant, i.e., at least 8 UI episodes in a week despite consistent use of the therapy. Participant does not wish to proceed to BoNT/A treatment, and their next step would be surgical intervention; OR; had an inadequate response to BoNT/A treatment in the opinion of the investigator and participant, i.e., at least 8 UI episodes in a week, and the last BoNT/A treatment for their NDO was at least 6 months prior to screening. Treatment with BoNT/A was not started more than 7 years ago, and their next step would be surgical intervention; Main Exclusion Criteria:
- Participant has previous or current tumor or malignancy affecting the spinal column or spinal cord, or any other nonstable cause of SCI
- Participant with active oral or genital herpes lesion. If the participant has an active oral or genital herpes infection this needs to be treated and healed first. The participant may be rescreened once the lesion has fully healed (at least 4 weeks after the lesion has healed)
- Participant had cancer therapy or radiotherapy ≤ 4 weeks prior to Screening and has toxicities/AEs attributable to previously administered cancer therapies that have not resolved or stabilized
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in United States.
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Sandrine Zourbas, Ph.D.No longer taking part
- Ohio State UniversityColumbus, United StatesContact: Iryna Crescenze, MDTaking people
- Rancho Los Amigos National Rehabilitation CenterDowney, United StatesContact: Evgeniy Kreydin, MDTaking people
- UTHealth Houston / TIRR Memorial HermannHouston, United StatesContact: Argyrios Stampas, MDTaking people
- Sidney Kimmel Medical CollegePhiladelphia, United StatesContact: Patrick Shenot, MDTaking people
About the trial
What the trial wants to find out
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
The 3 groups in the trial
- EG110A (low dose)Treatment being tested
Patients who Received EG110A (low dose)
Treatment: EG110A
- EG110A (Middle Dose)Treatment being tested
Patients who Received EG110A (middle dose)
Treatment: EG110A
- EG110A (Low-low Dose)Treatment being tested
Patients who Received EG110A (low-low dose)
Treatment: EG110A
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
- Plain-language title
- Testing EG110A injections for bladder leakage after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06596291, who can take part
- Record updated
- 3 September 2026